Loading the security overview…
Where the tokens are
Standardised from the company’s filings, newest period first, labelled with the company’s own fiscal calendar. A line the company does not report is left off rather than shown as zero; margins and free cash flow are worked out here, and only where every input is present.
| Line item | Q2 FY262026-06-30 | Q1 FY262026-03-31 | Q4 FY252025-12-31 | Q3 FY252025-09-30 | Q2 FY252025-06-30 | Q3 FY212021-09-30 | Q2 FY212021-06-30 | Q1 FY212021-03-31 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $263.71M | $216.17M | $292.89M | $216.83M | $181.40M | $100.83M | $85.70M | $80.80M |
| Cost of revenue | $84.12M | $74.83M | $71.97M | $69.33M | $67.71M | $0 | $0 | $0 |
| Gross profit | $179.60M | $141.35M | $220.91M | $147.51M | $113.69M | $100.83M | $85.70M | $80.80M |
| Gross margin | 68.1% | 65.4% | 75.4% | 68.0% | 62.7% | 100.0% | 100.0% | 100.0% |
| Research and development | $32.36M | $31.32M | $31.85M | $21.62M | $25.05M | — | — | — |
| Selling, general and administrative | $120.31M | $104.75M | $100.66M | $93.24M | $106.63M | $14.90M | $12.61M | $10.23M |
| Operating expenses | $152.67M | $136.07M | $132.50M | $114.86M | $131.67M | $47.58M | $41.88M | $38.78M |
| Operating income | $26.93M | $5.28M | $88.41M | $32.64M | −$17.99M | $53.25M | $43.81M | $42.02M |
| Operating margin | 10.2% | 2.4% | 30.2% | 15.1% | -9.9% | 52.8% | 51.1% | 52.0% |
| EBITDA | $33.46M | $10.35M | $92.70M | $37.51M | −$11.58M | $86.13M | $73.29M | $70.79M |
| Interest income | $6.82M | $6.83M | $7.02M | $7.36M | $1.62M | — | — | — |
| Interest expense | −$9.23M | −$12.81M | −$11.36M | −$13.51M | −$19.21M | −$11.46M | −$11.11M | −$11.17M |
| Income before taxes | −$614.00K | −$644.00K | $81.96M | $24.33M | −$71.79M | $54.83M | $39.80M | $37.18M |
| Income taxes | $23.00K | −$134.00K | $0 | — | $0 | $3.68M | $1.86M | $2.50M |
| Net income | −$637.00K | −$510.00K | $81.96M | $24.33M | −$71.79M | $51.16M | $37.94M | $35.74M |
| Net margin | -0.2% | -0.2% | 28.0% | 11.2% | -39.6% | 50.7% | 44.3% | 44.2% |
| EPS, basic | $0.00 | $0.00 | $0.29 | $0.09 | −$7.97 | $2.82 | $2.07 | $1.94 |
| EPS, diluted | $0.00 | $0.00 | $0.30 | $0.08 | −$7.97 | $2.79 | $2.04 | $1.91 |
| Diluted shares | 282.89M | 282.56M | 271.07M | 297.21M | 64.92M | 17.53M | 17.48M | 17.52M |
Figures describe Caris Life Sciences shares, not any token. As of Aug 5, 2026, from Massive's standardised financials. The company reports these figures; a token's issuer holds the shares and reports nothing of its own here.